Cancer stem cells—origins and biomarkers: perspectives for targeted personalized therapies
L Walcher, AK Kistenmacher, H Suo, R Kitte… - Frontiers in …, 2020 - frontiersin.org
The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest
over the last decades. In particular, the analysis of biomarkers in cancer patients within the …
over the last decades. In particular, the analysis of biomarkers in cancer patients within the …
Small-cell lung cancer: what we know, what we need to know and the path forward
Small-cell lung cancer (SCLC) is a deadly tumour accounting for approximately 15% of lung
cancers and is pathologically, molecularly, biologically and clinically very different from other …
cancers and is pathologically, molecularly, biologically and clinically very different from other …
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer
CA Stewart, CM Gay, Y **, S Sivajothi… - Nature cancer, 2020 - nature.com
The natural history of small-cell lung cancer (SCLC) includes rapid evolution from
chemosensitivity to chemoresistance, although mechanisms underlying this evolution …
chemosensitivity to chemoresistance, although mechanisms underlying this evolution …
[HTML][HTML] Lung cancers: molecular characterization, clonal heterogeneity and evolution, and cancer stem cells
Lung cancer causes the largest number of cancer-related deaths in the world. Most (85%) of
lung cancers are classified as non-small-cell lung cancer (NSCLC) and small-cell lung …
lung cancers are classified as non-small-cell lung cancer (NSCLC) and small-cell lung …
Crosstalk between small-cell lung cancer cells and astrocytes mimics brain development to promote brain metastasis
Brain metastases represent an important clinical problem for patients with small-cell lung
cancer (SCLC). However, the mechanisms underlying SCLC growth in the brain remain …
cancer (SCLC). However, the mechanisms underlying SCLC growth in the brain remain …
Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer
The Notch signalling pathway mediates cell fate decisions, and is tumour suppressive or
oncogenic depending on the context,. During lung development, Notch pathway activation …
oncogenic depending on the context,. During lung development, Notch pathway activation …
A biobank of small cell lung cancer CDX models elucidates inter-and intratumoral phenotypic heterogeneity
KL Simpson, R Stoney, KK Frese, N Simms, W Rowe… - Nature Cancer, 2020 - nature.com
Although small cell lung cancer (SCLC) is treated as a homogeneous disease, biopsies and
preclinical models reveal heterogeneity in transcriptomes and morphology. SCLC subtypes …
preclinical models reveal heterogeneity in transcriptomes and morphology. SCLC subtypes …
Vasculogenic mimicry in small cell lung cancer
Small cell lung cancer (SCLC) is characterized by prevalent circulating tumour cells (CTCs),
early metastasis and poor prognosis. We show that SCLC patients (37/38) have rare CTC …
early metastasis and poor prognosis. We show that SCLC patients (37/38) have rare CTC …
Biology and evolution of poorly differentiated neuroendocrine tumors
Neuroendocrine (NE) cancers are a diverse group of neoplasms typically diagnosed and
treated on the basis of their site of origin. This Perspective focuses on advances in our …
treated on the basis of their site of origin. This Perspective focuses on advances in our …
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
Small cell lung cancer (SCLC) is one of the most aggressive forms of cancer, with a 5-year
survival< 7%. A major barrier to progress is the absence of predictive biomarkers for …
survival< 7%. A major barrier to progress is the absence of predictive biomarkers for …